The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | THINK trial: Phase I results for NKG2D CAR-T therapy in AML
CYAD-01 is a CAR T-cell product based on the Natural Killer Group 2D (NKG2D) receptor. Here, David Sallman, MD, of the Moffitt Cancer Center, Tampa, FL, discusses the latest data presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, on the Phase I dose escalation THINK trial (NCT03018405), assessing the safety and clinical activity of multiple CYAD-01 administrations without prior preconditioning.
